BIOMAT Database Logo BIOMAT Database Logo

Quantitation of 3'-amino-3'-deoxythymidine (AMT), a toxic catabolite of 3'-azido-3'-deoxythymidine (AZT), by competitive ELISA. 1996

B Ferrua, and H Chakboub, and C Roptin, and R Garraffo, and A Faraj, and J Grassi, and R Guedj, and J P Sommadossi
Laboratoire de Pharmacologie Expérimentale et Clinique, Faculté de Médecine, Nice, France.

In the present study, a competitive ELISA technique was developed to specifically quantitate 3'-amino-3'-deoxythymidine (AMT), a toxic catabolite of 3'-azido-3'-deoxythymidine (AZT) detected in serum from AZT-treated patients. In order to eliminate cross-reacting AZT, serum sample was extracted with ethylacetate and then AMT was acetylated (Ac-AMT). A 5'-hemisuccinate-AMT-horseradish peroxidase conjugate was used as a tracer in the presence of anti-AMT rabbit antibodies which were raised against a 5' hemisuccinate-AMT-bovine serum albumin immunogen. Bound/free separation was achieved with an anti-rabbit IgG mouse monoclonal antibody insolubilized onto a microtiter plate. The limit of quantification of Ac-AMT was as low as 0.4 ng/ml in serum samples. This ELISA technique was applied for monitoring AMT plasma levels in patients receiving AZT therapy. The intra and inter-individual variations of the AZT/AMT plasma concentration ratios underlined the need for such a specific test in studying the formation of this toxic catabolite.

UI MeSH Term Description Entries
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D001667 Binding, Competitive The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements. Competitive Binding
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015224 Dideoxynucleosides Nucleosides that have two hydroxy groups removed from the sugar moiety. The majority of these compounds have broad-spectrum antiretroviral activity due to their action as antimetabolites. The nucleosides are phosphorylated intracellularly to their 5'-triphosphates and act as chain-terminating inhibitors of viral reverse transcription. 2',3'-Dideoxynucleosides,Dideoxyribonucleosides,ddNus,2',3' Dideoxynucleosides

Related Publications

B Ferrua, and H Chakboub, and C Roptin, and R Garraffo, and A Faraj, and J Grassi, and R Guedj, and J P Sommadossi
Clinical pharmacokinetics of 3'-azido-3'-deoxythymidine (zidovudine) and catabolites with formation of a toxic catabolite, 3'-amino-3'-deoxythymidine.
June 1992, Clinical pharmacology and therapeutics,
B Ferrua, and H Chakboub, and C Roptin, and R Garraffo, and A Faraj, and J Grassi, and R Guedj, and J P Sommadossi
Structure of 3'-azido-3'-deoxythymidine, AZT.
April 1988, Acta crystallographica. Section C, Crystal structure communications,
B Ferrua, and H Chakboub, and C Roptin, and R Garraffo, and A Faraj, and J Grassi, and R Guedj, and J P Sommadossi
Acute toxic effects of 3'-azido-3'-deoxythymidine (AZT) on normal and regenerating murine hematopoiesis.
January 1994, Experimental hematology,
B Ferrua, and H Chakboub, and C Roptin, and R Garraffo, and A Faraj, and J Grassi, and R Guedj, and J P Sommadossi
Reduction of 3'-azido-3'-deoxythymidine (AZT) and AZT nucleotides by thiols. Kinetics and product identification.
June 1994, The Journal of biological chemistry,
B Ferrua, and H Chakboub, and C Roptin, and R Garraffo, and A Faraj, and J Grassi, and R Guedj, and J P Sommadossi
Quantification of 3'-amino-3'-deoxythymidine, a toxic catabolite of 3'-azido-3'-deoxythymidine (zidovudine) in human plasma by high-performance liquid chromatography using precolumn derivatization with fluorescamine and fluorescence detection.
June 1994, Journal of chromatography. B, Biomedical applications,
B Ferrua, and H Chakboub, and C Roptin, and R Garraffo, and A Faraj, and J Grassi, and R Guedj, and J P Sommadossi
Catabolism of 3'-azido-3'-deoxythymidine in hepatocytes and liver microsomes, with evidence of formation of 3'-amino-3'-deoxythymidine, a highly toxic catabolite for human bone marrow cells.
February 1991, Molecular pharmacology,
B Ferrua, and H Chakboub, and C Roptin, and R Garraffo, and A Faraj, and J Grassi, and R Guedj, and J P Sommadossi
3'-azido-3'-deoxythymidine (AZT) monophosphate: an inhibitor of exonucleolytic repair of AZT-terminated DNA.
April 1993, Antimicrobial agents and chemotherapy,
B Ferrua, and H Chakboub, and C Roptin, and R Garraffo, and A Faraj, and J Grassi, and R Guedj, and J P Sommadossi
3'-Azido-3'-deoxythymidine (AZT) is a competitive inhibitor of thymidine phosphorylation in isolated rat heart and liver mitochondria.
July 2006, Biochemical pharmacology,
B Ferrua, and H Chakboub, and C Roptin, and R Garraffo, and A Faraj, and J Grassi, and R Guedj, and J P Sommadossi
3'-Azido-2',3'-dideoxyuridine (AzddU): comparative pharmacokinetics with 3'-azido-3'-deoxythymidine (AZT) in monkeys.
February 1990, AIDS research and human retroviruses,
B Ferrua, and H Chakboub, and C Roptin, and R Garraffo, and A Faraj, and J Grassi, and R Guedj, and J P Sommadossi
Role of human liver P450s and cytochrome b5 in the reductive metabolism of 3'-azido-3'-deoxythymidine (AZT) to 3'-amino-3'-deoxythymidine.
March 1998, Biochemical pharmacology,
Copied contents to your clipboard!